Lung-RADS v2022 — LDCT lung-screening nodule classification
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-LUNG-NODULE-LUNG-RADS |
|---|---|
| Type | Biomarker |
| Aliases | ACR Lung-RADS v2022LDCT nodule categoryLung-RADSLung-RADS for low-dose CT screeningLung-RADS v2022 — класифікація вузлів при НДКТ-скринінгу легень |
| Status | reviewed 2026-05-18 |
| Diseases | None declared |
| Sources | SRC-NCCN-NSCLC-2025 SRC-NCCN-SCLC-2025 |
Biomarker Facts
| Biomarker type | clinical_composite |
|---|---|
| Measurement | MethodLow-dose CT chest with structured Lung-RADS scoring: category 0 (incomplete), 1 (negative), 2 (benign), 3 (probably benign), 4A (suspicious), 4B (very suspicious), 4X (additional features ↑ malignancy), S (clinically significant non-lung) Unitscategorical Lung-RADS: 0 | 1 | 2 | 3 | 4A | 4B | 4X | S |
| Related biomarkers | None declared |
Notes
STUB. USPSTF Grade B (2021) — annual LDCT lung-screening ages 50-80, ≥20 pack-year history, current smoker or quit ≤15 y. Lung-RADS v2022 drives interval: 1-2 → annual; 3 → 6 mo; 4A → 3 mo + PET/biopsy consideration; 4B/4X → tissue diagnosis. NLST + NELSON demonstrated ~20-24% lung-cancer mortality reduction. Adherence to follow-up is primary determinant of program effectiveness.
Used By
No reverse references found in the YAML corpus.